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Abstract
Liver surgery has been evolving over the past years, 
and complication and mortality rates have gone down 
markedly. It has become one of the safest surgeries when 
strict selection criteria are applied. This relies on accurate 
and reliable preoperative assessment of liver function and 
the anatomical location of tumor, as well as its relation-
ship to important vascular structures. Precise volumetric 
measurement of liver segments also allows better predic-
tion of a successful liver resection. Various ways of embo-
lization of the right portal vein can hypertrophy the future 
liver remnant, increasing the safety profile markedly. At 
the same time, more and more evidence has shown that 
laparoscopic surgery can be the standard of care for most 
liver tumors. This can only be done with the help of ad-
vanced technologies, including different energy sources 
for parenchymal transection and stapling devices for ma-
jor pedicle and vascular control. On the other hand, liver 
transplantation is the definitive treatment for liver cirrho-
sis and its complications. There is evidence that the ap-
plication of liver transplantation can be extended to some 
controversial diseases, such as cholangiocarcinoma and 
colorectal cancers. Liver transplantation using the laparo-




Principle of Liver Surgery
The morbidity and mortality of liver surgery have 
markedly reduced over the past two decades. Modern 
liver surgery is still evolving; nonetheless, the principle 
remains the same. The aim of liver surgery is to achieve a 
clear resection margin in order to achieve the best survival 
result. However, the patient has to be fit to undergo gen-
eral anesthesia and has to have reasonable liver function 
and liver remnant reserve. Laparoscopic liver resection is 
emerging as a new modality to improve short-term out-
comes, if not the long-term outcomes.
Perioperative Management 
New Advances in Perioperative Assessment 
Liver surgery is different from other surgical proce-
dures involving other organs. Functional assessment of 
liver function is of paramount importance as poor liver 
function may preclude major liver operation. Preopera-
tive assessment includes general assessment of a patient’s 
fitness, liver function and tumor status. 
Liver Function Test 
Taking a thorough medical history is essential to un-
derstanding the general status of the patient. Clinical ex-
amination is composed of basic assessment of the patient’s 
condition. We should particularly look for the patient’s 
nutritional status and the presence of stigmata of chronic 
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liver disease. Splenomegaly signifies cirrhosis and severe 
portal hypertension, which may preclude major liver re-
section. 
Routine liver function test allows assessment of the 
underlying liver condition. Serum albumin and bilirubin 
levels are surrogate markers of synthetic and excretory 
functions, respectively. Platelet and white cell counts are 
reflective of portal hypertension. Raised serum alanine 
aminotransferase and aspartate aminotransferase levels 
indicate ongoing hepatocyte destruction rather than ac-
tual liver function. Prothrombin time or international 
normalized ratio is a real-time reflection of liver function 
[1]. The Child-Pugh score [2] is very useful for catego-
rizing patients based on the severity of underlying liver 
disease. It has five clinical and biochemical parameters 
measuring liver disease, and each measure is scored 1-3, 
with 3 indicating the most severe derangement (Table 1). 
The stratification of liver function allows surgeons’ deci-
sion on management of the liver malignancy according to 
the Hong Kong liver cancer staging system [3] or the Bar-
celona Clinic liver cancer staging classification [4-8]. In 
addition to liver function, renal function has been identi-
fied as one of the prognostic factors for hepatectomy [9].
6 www.avidscience.com
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Table 1: Child-Pugh score.
Indocyanine green (ICG) Retention Test 
ICG is a non-toxic, dark bluish-green tricarbocyanine 
dye. After injection, it is solely cleared from the blood by 
hepatocytes and is excreted into the bile without intrahe-
patic conjugation or enterohepatic circulation [10]. ICG 
test is mainly a measurement of liver blood flow and a re-
flection of intra hepatic portovenous shunt and sinusoi-
dal capillarization [11]. The ICG retention value at 15min 
(ICG R-15) after intravenous injection is about 10% in 
normal people. With ample experience in major hepatec-
tomy, the cutoff value for a safe major hepatectomy can 
be pushed to 17% in patients with adequate liver remnant 
volume [12]. Limited resection would allow higher ICG 
R-15 values, which can be as high as 40% [13]. The ICG 
retention value, however, should not be used singly but 
Classification 1 2 3
Serum albumin (g/L) >35 28 – 35 <28
Serum bilirubin (mmol/L) <34 34 – 51 >51
International normalized ratio <1.7 1.7 – 2.3 >2.3
Ascites Absent Controllable Refractory
Encephalopathy Absent Minimal to moderate 
(grade 1/2)
Severe (grade 3/4)
Points Class Severity Perioperative mor-
tality
5 – 6 A Least severe 10%
7 – 9 B Moderately severe 30%
10 – 15 C Most severe 82%
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should be combined with other clinical parameters (such 
as presence of portal hypertension) and liver biochemistry 






Figure 1: Indocyanine green test(A) Medication (B)Machine.
Operative Planning 
Various Imaging Techniques 
Ultrasound
Ultrasound is often used as the first imaging method 
for evaluation or screening of the liver, despite its lower 
sensitivity or specificity when compared with computed 
tomography (CT) or magnetic resonance imaging (MRI) 
[15-17]. However, low radiation, easy availability and low 
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cost allow its wide use. Ultrasound is the recommended 
screening tool for detection of hepatocellular carcinoma 
(HCC) in patients with cirrhosis, while CT or MRI is used 
for further detailed characterization and confirmation for 
lesions bigger than 1 cm [18-21]. Intraoperative ultra-
sound is particularly useful; it has greater sensitivity and 
allows better delineation and assessment of the relation-
ship between the tumor and intra-parenchymal vascula-
ture [22,23]. 
Contrast-Enhanced Ultrasound 
The use of contrast material allows dynamic images 
to be observed throughout the vascular phases of liver, 
which greatly improves the diagnostic accuracy of ultra-
sound. Various contrast agents are commercially availa-
ble, such as Sonovue® and Sonazoid®. Sonovue is a strictly 
intravascular agent, while Sonazoid is cleared by Kupffer 
cells. They are composed of microbubbles encapsulated by 
a stabilizing shell such as albumin, polymer, or phospho-
lipid. The microbubbles are miniature gas bubbles smaller 
than red blood cells (up to 7 micrometers in diameter) 
and therefore can pass through the capillary beds. The 
microbubbles act as blood-pool tracers, using ultrasound 
signals back-scattered from tissue to determine the ultra-
sound echogenicity [24].Contrast-enhanced ultrasound 
is particularly useful for clarifying obscure lesions that 
cannot be determined by CT or MRI. The enhancement 
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patterns depend on the microvascularization of the focal 
liver lesions, which can be identified as specific lesions 
with different characteristics based on the enhancement 
patterns in three vascular phases: arterial phase, portal ve-
nous phase, and late phase.
CT Scan
Multi-detector CT scan offers a best multiplanar and 
multiphasic imaging with fast scanning speed, but it car-
ries the risk of radiation exposure [25-27]. With injection 
of contrast, images of the liver at different phases (arterial, 
venous, delayed or any other desired phase) can be cap-
tured. Currently, all major HCC guidelines recommend 
multiphasic CT scan as the first-line imaging modality for 
the diagnosis of HCC [28-32].
CT Volumetry
CT volumetry of the liver was first performed on ca-
davers in 1979 by Heymsield [33]. It was shown to be ac-
curate within 5% of water displacement volumetry. CT is 
more commonly used than other modalities due to the 
relatively lower cost, greater accessibility, higher spatial 
resolution, and shorter acquisition time [34-36] [Figure 
2].
11




Figure 2: CT scan of liver volumetry(A) CT volumetry of left lateral 
section, with tumor at right lobe (area in red) (B) CT volumetry of 




MRI scan offers multiple contrast mechanisms. It 
shows the vascular and biliary anatomy and can be used to 
assess parenchymal pathology. It provides better informa-
tion of soft-tissue differentiation and tissue components, 
and is therefore useful in the detection and characteriza-
tion of indeterminate liver nodules, especially in a back-
ground of liver cirrhosis [37]. It also minimizes the risk 
of nephrotoxicity and eliminates concerns of radiation 
exposure [38]. Three types of contrast agents are available 
for the evaluation of cirrhosis-associated nodules, includ-
ing gadolinium-based extracellular contrast agents, super 
paramagnetic iron oxide (SPOI) contrast agents, and hepa-
tobiliary contrast agents. Gadolinium-based extracellular 
contrast agents contain low-molecular-weight gadolinium 
chelates that cause T1shortening; they are useful for the 
evaluation of tissue vascularity [39]. SPOI and hepatobil-
iary contrast agents are liver-specific contrast agents. SPOI 
agents show uptake in the reticulo edothelial system, while 
hepatobiliary agents (gadobenate dimeglumine or gadox-
etate disodium) show uptake in hepatocytes and demon-
strate biliary excretion [40]. Diffusion-weighted imaging 
is a functional imaging technique and is now one of the 
standard imaging sequences of a liver MRI. It gives infor-
mation on cellular architecture on a micrometer scale, and 
can evaluate the cellular density of hepatocellular nodules 
[37, 41].
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Positron emission tomography (PET) scan
PET scan with the tracer [18F]fluorodeoxyglucose 
(FDG) is one of the non-invasive diagnostic tools used 
for detection of various malignancies, including colonic, 
pancreatic, and lung tumors. The use of [18F] FDG PET 
may predict microvascular tumor invasion in candidates 
for liver transplantation [42-44]. The additional use of the 
tracer [11C] acetate has been proven specific for primary 
liver cancers. It has been shown to be negative for heman-
giomas, cholangiocarcinomas, secondary cancers from 
the colon, breasts or lungs, and carcinoids. It has been 
suggested that dual-tracer PET scan using [18F] FDG and 
[11C] acetate is incrementally better than single-tracer 
PET and has a complementary advantage [45,46]. The use 
of [18F]FDG PET may predict HCC with microvascular 
invasion [42,47] and allow better detection of tumors with 
poor differentiation. The additional use of [11C] acetate 
would improve the overall sensitivity of PET, allowing bet-
ter selection of candidates for liver transplantation [48].
 Concepts of portal vein embolization 
(PVE) and “associating liver partition 
and portal vein ligation for staged hepa-
tectomy” (ALPPS) 
PVE
PVE is indicated when a patient needs a right or ex-
tended right hepatectomy but has a relatively small future 
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liver remnant (FLR). With PVE, the size of an FLR can be 
increased. PVE, either in an open or percutaneous man-
ner, features embolization of the ipsilateral side of the por-
tal vein which supplies the liver lobe harboring the tumor 
[49,50] [Figure 3]. To date, there is still no strict value on 
the minimum volume of an FLR which allows major he-
patectomy to be performed safely. An FLR >35% of the 
estimated standard liver volume has been recommended 
for patients with cirrhosis, steatosis, or chronic hepatitis 
[51-58]. PVE is rarely required before extended left hepa-
tectomy or left trisectionectomy, since the right posterior 
section usually constitutes about 30% of the total liver vol-
ume [59,60]. The technique for embolizing the segment-4 
portal vein is crucial. If the vein is not properly blocked, 
suboptimal hypertrophy may result.
3(A)
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3 (B)
Figure 3: Percutaneous portal vein embolization(A) Portal vein em-
bolization in action (B) X-ray after portal vein embolization.
Liver Volume Assessment after PVE 
The FLR volume will be reassessed 4-8 weeks after 
PVE [61,62]. Rapid growth of the FLR in the first 3-4 
weeks is anticipated. Generally, an 8-30% enlargement 
over 2-6 weeks is expected [50,62-65]. Hypertrophy is 
usually slower in the presence of cirrhosis [66]. Studies 
comparing major hepatectomy with and without pre-
ceding PVE reported that comparable and even superior 
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long-term outcomes were achieved with PVE [55,67-73]. 
With PVE, patients who would have been considered in-
operable in the past because of their small FLR have the 
option of hepatectomy with reasonable long-term surgical 
outcomes.
Complications of PVE
PVE can be performed in an open or percutaneous 
manner. Open right portal vein ligation often renders the 
subsequent surgery difficult due to vascular or fibrotic ad-
hesions around the hilar structure. Open trans-ileocolic 
PVE features cannulation of the ileocolic vein with an-
tegrade PVE. Percutaneous portal vein cannulation with 
retrograde embolization is another option. Ipsilateral per-
cutaneous PVE is generally preferred because of the less 
invasiveness and an easier access to segment-4 portal vein 
branches [74,75]. Different ways of PVE all carry a risk 
of complication, such as main portal vein thrombosis. 
Prompt surgical intervention or anticoagulation is needed 
if the embolic agent crosses the contralateral side of the 
portal vein, which would cause liver failure in the case 
of bilateral PVE, resulting in death [76]. Hemorrhage or 
catastrophic bleeding at the puncture site may also occur, 
which also requires prompt surgical intervention. In addi-
tion, PVE induces inflammatory response near the hilar 
structure, which may increase the difficulty in dissection 
in the subsequent hepatectomy and raise the surgical risk.
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Sequential Transarterial Chemoem-
bolization and PVE 
PVE can be given to HCC patients with underlying 
cirrhosis, but hepatic regeneration and thus hypertrophy 
of the FLR would be impaired in the presence of cirrho-
sis [77-79]. On the other hand, it is likely that the arte-
rial flow in the segment with PVE will increase compen-
satorily, thereby stimulating tumor progression, as HCC 
is a hypervascular tumor mainly supplied by the hepatic 
artery blood flow [80-82]. To augment the effect of PVE 
and prevent tumor progression, the treatment “sequen-
tial transarterial chemoembolization and PVE” is used 
[67]. Studies comparing patients with and without this 
treatment showed that patients with the treatment had a 
higher rate of hypertrophy of FLR and a bigger increase 
of their FLR [67,68], and they also had a lower rate of tu-
mor progression as tumor necrosis was evident [83]. This 
treatment is not without risk; it could cause ischemic pa-
renchymal damage [84]. In general, however, it is feasible 
and safe, and it allows HCC patients who would otherwise 
be denied hepatectomy to undergo curative resection with 
reasonable postoperative 5-year overall and disease-free 
survival [66-68,85]. 
ALPPS
For hepatectomy, one of the limiting factors is inad-
equate volume of the FLR. Although the aforesaid meth-
18 www.avidscience.com
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ods are effective in inducing hypertrophy of the FLR, it 
takes several weeks for it to reach a satisfactory volume 
[50]. Tumor progression may occur before the FLR is 
large enough for hepatectomy. If a major vessel (such as 
the ipsilateral portal vein) is invaded by tumor, the tumor 
will progress in terms of days, and contralateral deposi-
tion and metastasis of the tumor will occur, rendering the 
tumor inoperable [81,82,86]. ALPPS is one of the main 
surgical innovations in recent years. The procedure, which 
was invented by chance, was initially carried out by Dr. 
Hans Schlitt from Germany in an intended extended right 
hepatectomy for hilar cholangiocarcinoma [87]. The pa-
tient had a small FLR, so palliative left hepaticojejunosto-
my was performed, with division of the liver parenchyma 
along the falciform ligament and ligation of the right por-
tal vein. On day 8 after the surgery, CT was performed. 
To Dr. Schlitt’s surprise, the left lateral section had grown 
enormously in size. The diseased portion of the liver was 
subsequently removed in another surgery. This novel tech-
nique was later termed “ALPPS” [88]. The idea of ALPPS 
is to speed up hypertrophy of the FLR (the left lobe or the 
left lateral section) by right portal vein ligation and in-situ 
splitting of the intended transection surface down to the 
inferior vena cava. Generally, the FLR regenerates to a vol-
ume adequate for a safe hepatectomy in days.
ALPPS was initially applied to relatively normal liv-
ers, such as in the case of colorectal liver metastasis. Lat-
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er it was also applied to livers with steatosis or cirrhosis 
[87,89-93]. A 70% increase in FLR volume has been re-
ported [94]. ALPPS is better than conventional PVE when 
the rate and the percentage of hypertrophy are concerned 
[95,96]. The shorter the interval between the two opera-
tions is, the less mature the adhesions will be, and hence 
the second operation will also be easier.
Most of the reported cases of ALPPS were on non-cir-
rhotic livers, and there has not been any report on the rate 
of hypertrophy in cirrhotic livers. However, one would 
anticipate that some patients would not have adequate hy-
pertrophy of the contralateral side, rendering the second-
stage operation impossible. ALPPS carries certain risks. 
The right hepatic artery could be injured, and liver failure 
could occur after right portal vein ligation. The Pringle 
maneuver would pose a further risk of liver injury and is 
thus not recommended. In the first-stage operation, adop-
tion of the anterior approach allows liver transection with-
out mobilization of the right lobe, thereby minimizing ad-
hesion formation [97], and the hilar plate is left untouched 
so as to minimize the chance of biliary complication. Bile 
leakage from the transection surface can result in biloma 
and increases the chance of infection and thus the risk 
of sepsis, which may forbid the second-stage operation. 
ALPPS is very technically challenging and demanding, 
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4 (C)
Figure 4: Procedure of ALPPS (A) Tumor at right lobe with small fu-
ture left lobe remnant (B) Right portal vein ligation with in-situ split 
(C) Completion right hepatectomy.
Courtesy of World Journal of Hepatology. [World J Hepatol. 2015 Aug 
28;7(18):2147-54.]
Indications for ALPPS 
ALPPS should be carried out with a curative intent. It 
is indicated for patients who have a large tumor load and 
a marginal FLR [95], even with tumor invasion of major 
vessels, such as the portal vein [91]. ALPPS renders some 
inoperable tumors potentially operable.
22 www.avidscience.com
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Morbidity and Mortality after ALPPS
Risks of complication and mortality are inevitable 
with any surgery; ALPPS is no exception. Perioperative 
mortality rates of 12-28% have been reported, which are 
overall higher than those of conventional major hepatec-
tomy [94,95,98,99]. A complication rate high at 50% has 
been recorded [98,100]. Complications include ascites, 
bile leakage, persisting cholestasis and sepsis, wound in-
fection, and other inflammatory and infective complica-
tions. ALPPS increases operability at the price of height-
ened morbidity and mortality. Keeping morbidity and 
mortality at the minimum requires careful patient selec-
tion, meticulous surgical technique, and accurate decision 
as to proceeding to the second-stage operation or not.
The long-term outcome of ALPPS is still unknown. 
Long-term overall survival and disease-free survival are 
still pending. Further studies as well as input from differ-
ent centers are required but not yet available. However, 
ALPPS has improved the operative rate, and it is hoped 
that it will improve the overall and disease-free survival 
of patients. Nonetheless, larger trials are needed to docu-
ment its efficacy, especially for HCC patients with back-
ground cirrhosis.
Operative Advances: Laparoscopic 
Hepatectomy 
Since the introduction of laparoscopic cholecystecto-
my in 1987 [101], the advantages of laparoscopic surgery 
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have been proven, which include less pain, more rapid re-
covery, earlier discharge, and a better cosmetic outcome 
[102,103]. The first anatomical laparoscopic hepatectomy 
was performed in 1996 for the resection of hepatic adeno-
ma [104]. Since then, the number of laparoscopic hepatec-
tomy has been increasing tremendously. When compared 
with open hepatectomy, laparoscopic hepatectomy has the 
advantages of less blood loss [105-107], shorter clamping 
duration, smaller chance of postoperative complications 
[108,109] and ascites [108,110], and shorter hospital stay 
[109,111].Laparoscopic major hepatectomy is a challeng-
ing procedure. However, as skills improve during its de-
velopment, the more difficult types of hepatectomy are 
being overcome. Use of the laparoscopic approach has 
been extended from resection of the left lateral section to 
hemi-hepatectomy, sectionectomy, segmentectomy, par-
tial resection of postero-superior segments, mono-seg-
mentectomy, and extended anatomical resection. Before 
hepatectomy could be purely done by the laparoscopic ap-
proach, the hand assisted procedure and the hybrid (lapa-
roscopic assisted) procedure were advocated to reduce 
the technical difficulty of pure laparoscopic hepatectomy 
[112-115]. Eventually, pure laparoscopic hepatectomy has 
been proven to be feasible in almost all segments [116-
126]. Nowadays, laparoscopic left lateral sectionectomy is 
regarded as a standard treatment option, and it will take 
some years for laparoscopic hepatectomy to become a 




A 10-level difficulty index system introduced by the 
Keio University group [129] provides a comprehensive 
stratification of HCC for pure laparoscopic hepatectomy, 
taking tumor size, tumor location, extent of resection, de-
gree of cirrhosis and proximity to major vessels into con-
sideration. Although all the procedures have been made 
feasible and easier due to the advancement of surgical 
skills and surgical equipment, operations with a high dif-
ficulty index should only be performed by experienced 
laparoscopic surgeons, while those with a low difficulty 
index are suitable for novices in laparoscopic hepatectomy 
(Figure 5).
Figure 5: Ten-level difficulty index system. [J Hepatobiliary Pancreat 
Sci. 2014 Oct;21(10):745-53.] (License for the current use purchased 
from John Wiley & Sons. License number 4233621391436).
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Surgical Adjunct 
Pneumoperitoneum is one of the most important ele-
ments in laparoscopic hepatectomy. The inflated pressure 
together with application of the Pringle maneuver reduces 
bleeding from the hepatic vein [130,131]. The dry opera-
tive field enables better visualization of vital structures 
and allows precise control of vessels and bile ducts.
Energy Sources and Surgical Devices
Modern dissecting tools with energy source allow 
careful and precise manipulation of liver tissue [132]. 
Examples of energy devices include Cavitron ultrasonic 
surgical aspirator (CUSA), water jet, ultrasonic scalpel, 
diathermy, monopolar sealer, bipolar diathermy, argon 
beam coagulator, radiofrequency pre-coagulator and mi-
crowave pre-coagulator (Figure 6). Caution must be tak-
en while deeper liver parenchymal transection is taking 
place, as excessive bleeding may occur if major vascular or 
biliary structure is encountered. This area is better dealt 
with a CUSA, the crush-clamp technique, or water-jet dis-
section with or without pre-coagulation using a monopo-
lar or bipolar device [133]. Up to date, no specific type 
of energy device has clearly emerged and none is recom-
mended over another. The use of energy device is to pro-
vide a precise dissection to separate vascular structures in 
a controlled fashion, and the different devices seem to be 




Figure 6: Use of surgical equipment. CUSA, Cavitron ultrasonic sur-
gical aspirator; MPC, microwave pre-coagulator; MS, monopolar 
sealer; ST, stapler; US, ultrasonic scalpel. [J Hepatobiliary Pancreat 
Sci. 2015 May;22(5):363-70.] (License for the current use purchased 
from John Wiley & Sons. License number 4233630434721)
CUSA
CUSA is specialized for isolation of intra hepatic vas-
culatures. Small vessels are eligible to be sealed and tran-
sected with an ultrasonic scalpel or cautery-based vessel 
sealer, whereas stapler hepatectomy can be used for major 
vessel sealing including division of the Glissonian sheath. 
Clips are acceptable for division of large vessels, with the 
warning of potential stapler misfire when crossing a prior 
clip placed in the liver parenchyma. Stapler hepatectomy 
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is usually limited to vascular pedicles, while it can be used 
as a major division device. Newly designed laparoscopic 
clips and electricity driver staplers allow smooth and non-
jerky motions of hemostasis, giving the operating sur-
geons full control [135,136].However, blind parenchymal 
transection using the stapler or an energy device without 
a clear operative field may lead to major bleeding and 
should therefore be avoided [137,138] [Figure 7].
Figure 7: Intraoperative use of stapling technique.
3D Imaging
Magnification with a high-definition video camera 
with a large display unit provides unprecedented clarity. 
With such clarity, small vessels and the bile duct can be 
clipped as in open surgery. One of the major limitations 
28 www.avidscience.com
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of conventional laparoscopy is the lack of depth percep-
tion and tactile feedback. 3D reproduction of the opera-
tive field is supposed to overcome most of the limitations 
of conventional laparoscopy [139-141].It may allow better 
depth perception and hand eye coordination, and there-
fore may enable accurate and swift dissection as well as 
better intra-corporal knotting for bleeding control or bil-
iary suture. Nonetheless, whether a 3D laparoscopic sys-
tem really benefits laparoscopic hepatectomy requires fur-








Figure 8: Laparoscopic hepatectomy (A) 3D laparoscopic system (B) 




Laparoscopic Imaging System: Intra-
operative ICG-Fluorescence Imaging 
Intraoperative ICG-fluorescence imaging allows fur-
ther identification of liver lesions as well as detection of 
complications. A laparoscopic imaging system that allows 
fusion ICG-fluorescence imaging enables identification 
of hepatic segmental boundaries and location of hepatic 
tumors. Tumors in the subcapsular region may not be lo-
cated by conventional imaging modalities preoperatively 
or intraoperatively. Intraoperative ICG-fluorescence im-
aging also allows detection of metastatic nodules that 
have regressed in size after neoadjuvant chemotherapy, as 
in the case of colorectal liver metastasis [142-145]. Un-
fortunately, ICG-fluorescence imaging is limited by the 
depth of lesions; intraoperative ultrasonography with en-
hanced contrast should be used to detect deeply seated 
lesions [146,147].The contrast difference seen on ICG-
fluorescence imaging allows identification of segmental 
boundaries of the hepatic parenchyma with and without 
blood perfusion, which guides surgeons in laparoscopic 
anatomical resection [148]. Furthermore, ICG-fluores-
cence imaging can be used as a form of intraoperative 
cholangiography to delineate the bile duct anatomy at the 
hepatic hilum and to detect the presence of bile leakage 
[149] [Figure 9].
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Figure 9: Machine for intraoperative laparoscopic indocyanine green 
test.
Liver Transplantation
Liver transplantation is the only life-saving procedure 
for patients with acute or chronic liver failure [150-152]. 
The long-term survival of HCC patients within well-
established criteria (such as the Milan criteria and the 
UCSF criteria) after liver transplantation has been proven 
[153-155]. The outcome of liver transplantation for hilar 
cholangiocarcinoma is also promising. The Mayo pre-
transplantation chemotherapy protocol has been shown 
to be beneficial to selected patients, with a 4-year recur-
rence-free survival rate of 65-70% [156-160].This protocol 
features external beam radiotherapy with 5-fluorouracil 
32 www.avidscience.com
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chemotherapy for three weeks, followed by intraluminal 
brachy therapy by iridium irradiation and maintenance 
chemotherapy (oral capecitabine). It aims to control dis-
ease progression and prevent metastasis before transplan-
tation. Patients with better tumor biology may be selected 
so that a better survival outcome of transplantation can be 
achieved. The idea of liver transplantation for colorectal 
liver metastasis was advocated by Hagness et al [161] and 
remains controversial as liver graft is generally a scarce 
resource. The idea can be implemented without sparking 
controversy only when the supply of liver grafts outstrips 
demand, such as in Norway, where there is a surplus of 
deceased-donor organs [162,163] [Figure 10].
10 (A)
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10 (B)
Figure 10: Hepatic venoplasty in liver transplantation (A) Middle and 
right hepatic veins (B) Completion of venoplasty of the middle and 
right hepatic veins.
Laparoscopic donor hepatectomy
Laparoscopic donor hepatectomy was first developed 
as left lateral sectionectomy for pediatric transplant pa-
tients [164]. Although being a minimally invasive sur-
gery, its safety profile was not different from the tradi-
tional open surgery [128]. However, with evolution and 
advancement of the procedure, pure laparoscopic full left 
[165-167] and right hepatectomies[168-170] with success 
were reported. The short-term outcomes in donors have 
markedly improved by the laparoscopic means. However, 
the benefit of laparoscopic donor hepatectomy for recipi-




Modern liver surgery has become safer. It is also be-
coming more aggressive, yet relatively minimally invasive. 
Proper preoperative assessment of the patients’ general 
condition, liver function and tumor status is essential for 
better decision making in liver surgery.
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